stockrow
Saturday 7 November 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million.
- EPS
- −8.22%
- Free cash flow
- +10.0%
Quarter to September 2026, against a year earlier
9.42
0.61
+6.92%
Follow CTNM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 50 | — | — | — | — | 5 | 5 | 5 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (24) | 23 | (42) | (60) | (63) | +35.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 46.34 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (24) | 23 | (42) | (60) | (63) | +35.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 21.65 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (10.81) | 1.36 | (2.18) | (2.17) | (1.77) | (41.5%) | ||||||
| Cash flow | — | — | — | — | — | — | (8.97) | 8.38 | (1.70) | (2.00) | (1.35) | (39.4%) | ||||||
| Capex | — | — | — | — | — | — | (0.05) | (0.18) | (0.03) | (0.01) | (0.01) | (46.0%) | ||||||
| Free cash flow | — | — | — | — | — | — | (9.02) | 8.20 | (1.72) | (2.01) | (1.36) | (39.4%) | ||||||
| Book value | — | — | — | — | — | — | (41.56) | (29.42) | 10.23 | 9.42 | 6.39 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 2 | 2 | 19 | 28 | 35 | +131.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 1.35 | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | — | — | 1.47 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | (5.03) | — | — | (2.27) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (20) | 19 | (33) | (55) | (52) | +40.1% | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | +25.1% | ||||||
| Free cash flow | — | — | — | — | — | — | (20) | 19 | (33) | (56) | (52) | +40.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 41 | 122 | 196 | 258 | 242 | +84.9% | |||||
| Net debt | — | — | — | — | — | — | (43) | (125) | (203) | (263) | (244) | +82.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (93) | (68) | 198 | 261 | 245 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | 3.48 | (24.62) | (24.51) | (28.34) | (24.5) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (4,845.62) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (3.90) | (64.95) | (26.13) | (29.80) | (26.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 31 | 41 | 51 | — | +28.3% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 1.61 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Jun 2023 · fundamentals updated 5 Nov 2026
Contineum Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRXB TRex Bio Inc. | $356.5M | — | — | — | — | — | — | — | Compare |
| AVTX Avalo Therapeutics, Inc. | $355.6M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| RZLT Rezolute, Inc. | $352.1M | — (loss-making) | — | — | n/m | +40.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTNM Contineum Therapeutics, Inc. | $345.9M | — (loss-making) | — | — | n/m | +10.04% (above 0%: growing) | 100.00% | 0.00% | |
| MPLT MapLight Therapeutics, Inc. | $345.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| AGMB AgomAb Therapeutics NV | $343.3M | — | — | — | — | — | — | — | Compare |
| SRZN Surrozen, Inc. | $340.9M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | Compare |
| AVIR Atea Pharmaceuticals, Inc. | $338.5M | — (loss-making) | — (loss-making) | +295.16% (above 0%: growing) | n/m | +85.53% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OBIO Orchestra BioMed Holdings, Inc. | $337.8M | — (loss-making) | — (loss-making) | −89.47% (below 0%: shrinking) | n/m | −25.87% (below 0%: shrinking) | 71.59% | (25,404.55%) | Compare |
| Median of peers | $344.5M | — | — | +112.51% | — | +9.49% | 55.73% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Ownership
Directors and executive officers, together
7.90%
Entities affiliated with Suvretta Capital Management, LLC
8.70%
Entities affiliated with Janus Henderson Group plc
7.50%
Entities affiliated with Balyasny Asset Management L.P.
7.10%
Entities affiliated with RA Capital Management, L.P.
6.70%
Johnson & Johnson Innovation – JJDC, Inc.
6.00%
Entities affiliated with Franklin Advisers, Inc.
5.70%
Entities affiliated with Millennium Management LLC
5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement